GenesisCare to offer new PSMA PET test

2021 01 16 00 14 5464 Prostate Cancer 400

GenesisCare will expand testing for prostate cancer nationwide with the use of Pylarify (F-18 DCFPyL), a PET radiopharmaceutical designed to target prostate-specific membrane antigen (PSMA).

Pylarify received approval from the U.S. Food and Drug Administration in May, 2021.

GenesisCare will expand access to the radiotracer at its Florida, South Carolina, and Texas centers, the company said.

The first Pylarify injection in a patient at a GenesisCare site took place on June 3, 2021, the company added.

Page 1 of 598
Next Page